Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Multicenter Study
Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.
To evaluate the tolerability of escalating doses of stereotactic body radiation therapy in the treatment of localized prostate cancer. ⋯ Dose escalation to 50 Gy has been completed without DLT. A multicenter phase II trial is underway treating patients to 50 Gy in five fractions to further evaluate this experimental therapy.
-
Randomized Controlled Trial Multicenter Study
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken. ⋯ The addition of cetuximab to FOLFIRI as first-line therapy improves survival in patients with KRAS wild-type mCRC. BRAF tumor mutation is an indicator of poor prognosis.